Melinta Therapeutics is an antibiotics-focused company that develops and commercializes antibiotics to overcome drug-resistant infections. Its four marketed products include Baxdela (delafloxacin), Vabomere (meropenem and vaborbactam), Orbactiv (oritavancin), and Minocin (minocycline) for injection. The Company also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market.
Melinta Therapeutics total Funding
Melinta Therapeutics latest funding size
Time since last funding
|2 years ago|
Melinta Therapeutics investors
|Warburg Pincus, Cardinal Partners, SR One, ABS Ventures, Axiom Ventures, Oxford Bioscience Partners, MedImmune Ventures, Sanofi Aventis, Vatera Healthcare Partners, Vox Equity Partners I, EuclidSR Partners, Hercules Capital|
When was Melinta Therapeutics founded?
Melinta Therapeutics was founded in 2000.
Who are Melinta Therapeutics key executives?
Melinta Therapeutics's key executives are Jennifer Sanfilippo, David Gill and Peter Milligan.
How many employees does Melinta Therapeutics have?
Melinta Therapeutics has 146 employees.
Who are Melinta Therapeutics competitors?
Competitors of Melinta Therapeutics include Retrophin, Palatin Technologies and GBT (Global Blood Therapeutics).
Where are Melinta Therapeutics offices?
Melinta Therapeutics has an office in New Haven.
How many offices does Melinta Therapeutics have?
Melinta Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies